18-Hydroxycorticosterone as a marker for primary hyperaldosteronism.
An assay for the measurement of 18-hydroxycorticosterone (18-OHB) in plasma has been validated. The method involves extraction of plasma with dichloromethane, thin layer chromatography and radioimmunoassay with an iodinated 18-hydroxycorticosterone-3-carboxymethyloxime ligand. The plasma concentration of 18-OHB was measured in 16 patients with primary hyperaldosteronism and 20 control subjects. After overnight recumbency a significantly higher mean concentration of 18-OHB was found in the samples taken from the patients than in those from the control subjects. The degree of elevation did not clearly discriminate between patients with a unilateral adenoma and those with bilateral adrenal hyperplasia. A significant anomalous postural decrease in the 18-OHB concentration occurred in 10 of the 13 patients with an adenoma, whereas there was a significant postural increase in the three patients with hyperplasia.
Lapworth
R
R
Department of Chemical Pathology, St Mary's Hospital, London, UK.
Short
F
F
James
V H
VH
D015069:18-Hydroxycorticosterone / Q000097:blood*; D000236:Adenoma / Q000097:blood / Q000150:complications; D015415:Biomarkers / Q000097:blood; D003345:Corticosterone / Q000031:analogs & derivatives*; D003429:Cross Reactions; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D006965:Hyperplasia / Q000097:blood / Q000150:complications; D008297:Male; D011187:Posture; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood
D015415:Biomarkers; D015069:18-Hydroxycorticosterone; D012083:Renin; D003345:Corticosterone